Cover story
-
A top-notch inhibitor
November 19, 2009, Volume 2 / Number 45
The previously intractable Notch pathway looks to be opening as a Harvard team has described a way to specifically inhibit Notch signaling and UCSD researchers have identified a role for NOTCH3 in pulmonary arterial hypertension. Also, Aileron Therapeutics has moved the Harvard technology into preclinical programs for a range of indications beyond cancer.
- Read more
-
-
Analysis
APC mutants for ALS
University of Rochester researchers suggest mutant forms of activated protein C could improve outcomes in ALS, and they point to a possible role of microglia in the etiology of the disease. The results could expand the number of indications addressed by ZZ Biotech's portfolio of APC mutants.
gp130's sensitive side
Medical University Innsbruck researchers suggest that inhibiting the gp130 pathway could help manage certain types of pain as well as exert a therapeutic effect in cancer and inflammation. The key will be to block the pathway without disrupting the body's natural immune response.
Warming up to lung transplants
University of Toronto researchers have combined ex vivo IL-10 gene therapy with an organ preservation system from Vitrolife AB to repair damage in donor lungs and make them suitable for transplant. The approach could expand the supply of donor lungs and be applied to other donor organs.
